Biomerica (NASDAQ:BMRA) posted its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative return on equity of 40.08% and a negative net margin of 52.42%.
BMRA stock traded down $0.35 during mid-day trading on Friday, hitting $5.71. 4,579 shares of the stock were exchanged, compared to its average volume of 1,687,348. The business has a fifty day moving average price of $5.75 and a 200 day moving average price of $7.05. Biomerica has a 12 month low of $2.05 and a 12 month high of $23.39. The stock has a market capitalization of $67.11 million, a price-to-earnings ratio of -17.66 and a beta of -0.47.
Several equities analysts recently commented on the company. B. Riley reduced their target price on Biomerica from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Aegis dropped their price target on Biomerica from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, October 19th. Finally, Colliers Securities began coverage on Biomerica in a research note on Tuesday, November 10th. They set a “buy” rating and a $13.00 price target for the company.
In other news, Director Catherine Coste purchased 9,100 shares of the company’s stock in a transaction on Monday, October 26th. The stock was purchased at an average price of $5.45 per share, with a total value of $49,595.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 23.70% of the company’s stock.
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Featured Story: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.